Fair valuation.

One that’s less than good. This look at California cancer registry data suggests the biggest driver of achieving high-value care for resectable pancreatic cancer has less to do with NCI-branding and more to do with receiving multiagent adjuvant chemo. | Bateni, JAMA Surg 2019